Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies for PF708 (biosimilar, teriparatide)

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies for PF708 (biosimilar, teriparatide)

Shots:

  • Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively
  • The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories
  • PF708 is a biosimilar referencing Eli Lilly’s Forteo/ Forsteo, being developed pursuant to the 505(b)(2) regulatory pathway in the US and has received FDA’s approval in Oct’2019. Alvogen in partnership with Saja has submitted MAA for PF708 to the Kingdom of Saudi Arabia’s Saudi Food and Drug Authority

Click here to­ read full press release/ article | Ref: Alvogen | Image: Pharmacompass